Bernadette Connaughton - May 1, 2025 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
Director
Signature
/s/ James Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
May 1, 2025
Transactions value $
$0
Form type
4
Date filed
5/2/2025, 04:02 PM
Previous filing
Jun 3, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Connaughton Bernadette Director C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO /s/ James Oehler, Attorney-in-Fact 2025-05-02 0001662521

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Award $0 +4.17K +8.9% $0.00 51K May 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Award $0 +5.75K $0.00 5.75K May 1, 2025 Common Stock 5.75K $60.03 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.
F2 Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.